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Abstract: Novel antibiotics are needed to overcome the challenge of continually evolving bacterial
resistance. This has led to a renewed interest in mechanistic studies of once popular antibiotics
like chloramphenicol (CAM). Chloramphenicol acetyltransferases (CATs) are enzymes that
covalently modify CAM, rendering it inactive against its target, the ribosome, and thereby causing
resistance to CAM. Of the three major types of CAT (CATI-III), the CAM-specific CATIII has been
studied extensively. Much less is known about another clinically important type, CATI. In addition
to inactivating CAM and unlike CATIII, CATI confers resistance to a structurally distinct antibiotic,
fusidic acid. The origin of the broader substrate specificity of CATI has not been fully elucidated.
To understand the substrate binding features of CATI, its crystal structures in the unbound (apo)
and CAM-bound forms were determined. The analysis of these and previously determined CATI-FA
and CATIII-CAM structures revealed interactions responsible for CATI binding to its substrates and
clarified the broader substrate preference of CATI compared to that of CATIII.
Keywords: antibacterial agent; antibiotic resistance; chloramphenicol acetyltransferase; fusidic
acid; specificity; substrate recognition
Introduction
Chloramphenicol (CAM) [Fig. 1(A)] is a potent broad-
spectrum antibacterial agent. Since its isolation from
Streptomyces venezuelae in 1948,1 CAM was one of
the primary agents used to treat many infections in
the decades that followed. To date, despite its rela-
tively high toxicity,2 CAM is used in many countries
because of its affordability and its broad spectrum of
activity. In the Western world, CAM is used in treat-
ment of ophthalmic infections and as a last resort in
cases of life-threatening brain infections, such as
those caused by Neisseria meningitidis, which do not
respond to other agents. CAM’s ability to cross the
blood-brain barrier makes it a potent therapeutic
against brain infections. Because of the emergence of
pathogens resistant to multiple drugs, CAM is now
being reconsidered as a wider-spectrum therapeutic.3
CAM inhibits protein biosynthesis by binding to
the 50S subunit of the bacterial ribosome. Recent
crystal structures of the 50S subunit of the Esche-
richia coli and Thermus thermophilus ribosome in
complex with CAM revealed that CAM binds to the
A-site of the 50S subunit and occupies the binding
site for the amino-acyl moiety of the A-site tRNA.4,5
The 3-hydroxyl of CAM is buried in the interface
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with the ribosome through direct hydrogen bonding,
potassium ion-mediated electrostatic interactions, as
well as through van der Waals interactions with the
RNA phosphosugar backbone.4,5 The 1-hydroxyl of
CAM forms hydrogen bonds with RNA bases. There-
fore, any modification of the 1-hydroxyl or the
3-hydroxyl of CAM is predicted to be disruptive of
CAM-ribosome binding.5 Bacterial resistance to CAM
is caused by the chromosomally or plasmid-encoded
enzyme chloramphenicol acetyltransferase (CAT) that
catalyzes the transfer of an acetyl group from acetyl-
coenzyme A (AcCoA) to the 3-hydroxyl group of CAM
[Fig. 1(B)].6 A subsequent slow, non-enzymatic transfer
of this acetyl group to the neighboring 1-hydroxyl
group allows for a second CAT-catalyzed acetyl trans-
fer from AcCoA onto the 3-hydroxyl group of the same
CAM molecule, resulting in a di-acetylated CAM.7,8
However, a single acetylation of CAM is sufficient to
abolish its affinity for the ribosome9 as explained by
the above-mentioned structural observations.4,5
CAT proteins are historically divided into three
types: CATI, CATII, and CATIII, with all three types
capable of catalyzing the acetyl transfer to CAM to
generate 3-O-acetyl-CAM. Genomic analysis of differ-
ent CAT sequences indicates that the boundaries
between these CAT types are not sharp. Members of
the CATI family are present in many important patho-
gens such as E. coli, Shigella flexneri, Serratia marces-
cens, and Salmonella enterica. CATI family enzymes
display high sequence conservation among themselves
(e.g. S. flexneri and S. marcescens CATI proteins are
98% and 99% identical to E. coli CATI, respectively);
however, they display only a modest sequence identity
to CATII (46%) and CATIII (32–47%) (Fig. 2). The
CATII family is not easily distinguishable from CATIII
and has been defined historically only through its
extreme susceptibility to thiol-modifying agents com-
pared with that of CATI and CATIII.
11 There are no
obvious additional Cys residues or other sequence
features in CATII distinguishing it from the CATIII var-
iants. A slight variation in the pKa of the Cys31
(in CATIII nomenclature), the only Cys in vicinity of
the substrate or the cosubstrate binding sites, was
suggested to be responsible for the difference in reac-
tivity with thiol-modifying agents,12 although there is
no evidence confirming this idea.
The sequence differences between CATI and
CATIII include several substitutions in the binding
Figure 1. (A) Chemical structures of CAM and FA. (B) Acetylation of CAM by CATs.
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site (Fig. 2), potentially resulting in positional differ-
ences of CAM bound to these two proteins. A major
consequence of this divergence is reflected in differ-
ent substrate selectivities of CATI and CATIII. In
addition to binding and modifying CAM,6 CATI,
unlike CATIII, binds a much bulkier antibiotic,
Figure 2. Sequence alignment10 of CATI, CATII, and CATIII enzymes from various bacteria (EC, Escherichia coli; YP, Yersinia
pestis; KP, Klebsiella pneumoniae; SM, Serratia marcescens; SF Shigella flexneri; PM, Proteus mirabilis; HI, Haemophilus
influenzae; SE, Salmonella enterica; VS, Vibrio sp.; BC, Bacillus cereus; BA, Bacillus anthracis; SP, Streptococcus
pneumoniae; EF, Enterococcus faecium; LM, Listeria monocytogenes; SA, Staphylococcus aureus; CD, Clostridium difficile;
CB, Clostridium botulinum; CT, Clostridium tetani). Important residues in the active site that are either conserved or non-
conserved (vary) between CATI and CATIII are indicated by red and blue circles, respectively. Residues involved in CAM and
FA binding are marked by orange and yellow circles, respectively.
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fusidic acid (FA).13 FA [Fig. 1(A)] is a steroidal anti-
bacterial agent that is used topically or systemically,
usually against infections caused by Gram-positive
pathogens. CATI does not modify FA; rather, it
sequesters it through binding by its CAM binding
site. This type of mechanism of resistance through
sequestration is not uncommon and has been
observed for other antibiotics such as bleomycin and
thiocoraline.14–18 Kinetic studies have shown that
FA competes with CAM for binding to CATI, but not
the other CAT types.13 Various bile salts and some
triphenylmethane dyes also exhibit similar competi-
tive binding to CATI, but not to CATII/III.
13,19–21
CATI plays an important role in antibiotic
resistance of many pathogenic bacteria. In addition,
CATI has been used as a biochemical and proteomic
tool in a number of systems22–26 and as a common
CAM-resistance marker encoded in laboratory plas-
mids. Despite its importance in drug resistance and
biotechnology, CATI
27 has been much less investi-
gated than CATIII. Structural and biochemical
studies of CATIII
28–34 have been mostly used to under-
stand general features of CATI proteins. Despite this
progress, differences in the substrate selectivity
between CATI and CATIII remain unclear in absence
of analysis of CATI-CAM and CATI-FA structures.
Herein we report crystal structures of CATI
alone (apo) and in complex with CAM, which explain
how CATI binds CAM despite differences in its bind-
ing site residues from those in CATIII. Analysis of
these structures along with that of the structure of
CATI in complex with FA (deposited in the Protein
Data Bank (PDB) by Roidis and Kokkinidis; acces-
sion code: 1Q2335) provides an explanation of the dif-
ferences in substrate preference among CAT types.
Results
Overall structure of CATI
E. coli CATI protein was initially co-crystallized with
CAM in the P1 space group (Table I). Molecular
replacement using either a monomer or trimer of
apo-CATI (from the structure of a serendipitous com-
plex of the nitric oxide synthase oxygenase domain
with CATI; PDB code: 1NOC
37) as a search model
did not yield a solution. This complication likely
arose due to the presence of several copies of the
protein molecules within a very large unit cell. Fur-
ther crystallization trials yielded crystals of CATI
alone in the P21 space group with a smaller asym-
metric unit. These crystals grew under conditions
similar to those of the CATI-CAM crystals. Molecular
replacement with a CATI trimer from the 1NOC
entry as a search model, yielded an apo-CATI struc-
ture with three CATI trimers in the asymmetric unit
(Table I). This three-trimer structure was then suc-
cessfully used as a molecular replacement search
model to determine the structure of the CATI-CAM
complex in the P1 crystal form. The asymmetric unit
of the P1 crystal form contained six CATI-CAM
trimers. The crystal structure of the apo-CATI and
that of the CATI-CAM complex were refined to 3.2 A˚
and 2.9 A˚ resolution, respectively (Table I).
The structure of CATI protein in the apo form
reported here is very similar to the structure of apo-
CATI (PDB code: 1NOC) used for the molecular
Table I. X-ray Diffraction Data Collection and Refinement Statistics for apo-CATI and CATI-CAM Structures
Apo-CATI CATI-CAM
Data collection
Space group P21 P1
Number of trimers per asymmetric unit 3 6
Unit cell dimensions
a, b, c (A˚) 115.2, 102.7, 114.1 107.5, 114.5, 114.5
a, b, c () 90, 119.9, 90 119.9, 97.8, 98.7
Resolution (A˚) 50.0–3.2 (3.3–3.2)a 50.0–2.9 (3.0–2.9)a
I/r 9.3 (2.1) 14.3 (2.3)
Completeness (%) 98.4 (86.1) 87.3 (85.0)
Redundancy 4.3 (3.5) 1.7 (1.7)
Rmerge 0.15 (0.476) 0.06 (0.38)
Number of unique reflections 35,818 82,522
Structure refinement statistics
Resolution (A˚) 40.0–3.2 35.0–2.9
R (%) 23.8 24.0
Rfree (%) 30.1 30.9
Bond length deviation (RMSD) from ideal (A˚) 0.009 0.006
Bond angle deviation (RMSD) from ideal () 1.08 0.907
Ramachadran plot statisticsb
% of residues in most allowed regions 84.9 88.7
% of residues in additional allowed regions 12.9 10.5
% of residues in generously allowed regions 2.3 0.8
% of residues in disallowed regions 0 (0 residues) 0 (0 residues)
a Numbers in parentheses indicate the values in the highest-resolution shell.
b Indicates Procheck statistics.36
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replacement (Ca RMSD ¼ 0.7 A˚) and to another pre-
viously deposited structure of apo-CATI (PDB code:
1PD5; Ca RMSD ¼ 0.7 A˚). Furthermore, the struc-
tures of apo-CATI are highly similar to the structure
of CATI in complex with CAM (Ca RMSD  0.4 A˚),
suggesting that no major protein conformational
changes occur upon CAM binding. Analogously, no
major conformational differences were observed for
CATIII in the apo and the CAM-bound forms.
28 The
overall fold and the oligomeric organization of CATI
[Fig. 3(A)] resemble those of the previously charac-
terized CATIII
28 variant. Three identical monomers
of CATI form a trimer with a 3-fold rotational sym-
metry. The overall trimeric scaffold is formed by
three 7-stranded b-sheets, each of which is formed
by six strands (b6, b5, b7, b9, b10, and b2) from one
monomer and one strand (b8) from another mono-
mer [Fig. 3(B)]. In each monomer, this b-sheet is
flanked on the outside by five a-helices and a small
three-stranded b-sheet. In the trimeric core, the
aliphatic parts of buried Asp157 side-chains (in
strand b8) of the three monomers come together to
form intimate hydrophobic contacts with each other,
while their carboxyl groups are engaged in intricate,
asymmetric network of hydrogen bonding interac-
tions with the side-chains of Ser155 and Asn159.
The hydrophobic interactions between the Asp157
residues are likely critical for complex stability as
this residue is either an Asp or an Asn in most
CATI/CATIII proteins. Ser155 could however be sub-
stituted by a Gly (Fig. 2). The side-chains of Asp157
residues are distorted so that the carboxyl groups
Figure 3. (A) Overall fold and trimeric organization of CAM-bound form. The strands of the b-sheets comprising the central
scaffold are marked. The CAM molecule and its molecular surface are shown in blue. (B) A close-up view of the active site at
the interface of two monomers in CATI-CAM structure. Substrate binding residues of the binding monomer and catalytic
monomer are colored in green and orange, respectively. A few highly conserved residues involved in catalysis are marked in
red. (C) A representative view of one of the CATI active sites. The violet mesh clearly defining the CAM molecule (blue sticks)
is Fo-Fc omit electron density generated without the CAM in the model and contoured at 3r. (D) A zoomed in view of the
active site shown in panel C, depicted in a slightly different orientation. (E) A schematic view of residues of the CATI active
site and their interactions with CAM. Hydrogen bonds and hydrophobic contacts are marked by black dashed lines and the
grey hashed lines, respectively. The color coding is consistent with that of panel B. An interactive view is available in the
electronic version of the article.
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form hydrogen bonds with their own backbone am-
ide NH moieties justifying a weaker conservation of
the Ser155. As the side-chains in these b-strands are
generally buried away from the solvent, their identi-
ties are well conserved among CAT homologs.
Chloramphenicol interactions in the active site
Upon trimerization, the active site is formed at the
interface of two b-sheets predominantly with resi-
dues from strands b6, b5, b7, b9, and b8 of one
monomer (termed as the binding monomer) and
strands b2 and b10 of the other (the catalytic mono-
mer). Each trimer contains three identical substrate
binding sites [Fig. 3(A)]. The nature of this con-
served trimeric assembly strongly suggests that
CATI monomers either require trimeric assembly for
proper folding or, if folded, CATI would be catalyti-
cally active only in the context of a trimer. Indeed,
monomeric mutants of the CATIII, whose overall fold
is highly similar to that of CATI, were shown to be
catalytically inactive.38 Below, we discuss features of
the active site of CATI and highlight its differences
from that of CATIII that specify the distinct sub-
strate recognition properties of these two proteins.
In the structure of CATI-CAM complex, all three
active site pockets of the CATI trimer are occupied
with CAM molecules [Fig. 3(A)], whose positions are
clearly defined in the electron density map
[Fig. 3(C,D)]. One of the two monomers forming a
binding site (called here the binding monomer) pro-
vides the majority of the residues (Cys91, Phe102,
Ser104, Phe134, Phe144, Ser146, Leu158, and
Val170) involved in binding of the CAM while the
other one (called here the catalytic monomer) pro-
vides His193, which has been demonstrated to be
one of the primary conserved catalytic residues7,39,40
[Fig. 3(B)]. A few other residues from the catalytic
monomer (Phe25 and Cys31) also provide an impor-
tant CAM-binding surface in the binding pocket.
The disposition of the conserved catalytic residues
[e.g. His193, Ser146, and Asp197; highlighted in red
in Fig. 3(B)] in the CATI-CAM structure is highly
similar to that observed previously in CATIII-CAM
complex.41 The position of His193, the likely general
base, relative to the bound CAM is identical to its
counterpart in CATIII (His195). The Ne2 atom of
His193 is located 2.7 A˚ away from the 3-hydroxyl of
CAM [Fig. 3(E)]. The side-chain of His193 is in a
distorted conformation (His193 v1 ¼ 150.2 and
v2 ¼ 41.0 with CAM bound and v1 ¼ 142.0 and
v2 ¼ 32.6 with FA bound). This conformation
likely ensures that the imidazole ring is aligned
appropriately for abstracting the 3-hydroxyl proton
of CAM, promoting a nucleophilic attack by the oxy-
gen on the acetyl group carbonyl of AcCoA,29,30,34
similarly to the proposed mechanism of the CATIII
variant.40 The imidazole ring of His193 is positioned
at a proper distance (approximately 3.6 A˚) for a face-
to-face p-p stacking contact with Phe25. This overall
structural arrangement of the catalytic monomer for
proper positioning of His193 at the subunit interface
is stabilized by several interactions that include a
chain of hydrogen bonds between His193, Asp197,
Arg18, and the backbone carbonyl oxygen of Ala194
[Fig. 3(E)]. The conserved Ser146 (another catalyti-
cally important residue) of CATI is positioned simi-
larly in the active site of all three CATI structures,
and likely stabilizes the transition state oxyanion by
donating a hydrogen bond (possibly water-mediated
in CATI), as proposed for Ser148 of CATIII.
42
The sequence alignment of CATI and CATIII from
E. coli demonstrates that of the 20 amino acid resi-
dues lining the CAM binding site, 9 are different
between the two types (Fig. 2, blue circles). These
differences [Ala24 (CATIII, Phe24), Phe25 (CATIII,
Tyr25), Val28 (CATIII, Arg28) Ala29 (CATIII, Leu29),
Cys91 (CATIII, Gln92), Tyr133 (CATIII, Leu134),
Phe144 (CATIII, Asn146), Phe166 (CATIII, Tyr168),
and Val170 (CATIII, Ile172)] are significant as they
include changes in the size and hydrophobicity of the
residues. Remarkably, despite these differences, CAM
binding affinities for CATI and CATIII appear to be
very similar.43 Furthermore, the superposition of
CATI-CAM and CATIII-CAM structures demonstrates
that the orientations of the CAM molecule in the
active sites of the two proteins are nearly identical.
The p-NO2 group of CAM is solvent exposed when
bound in the CATI active site and the aromatic ring
rests on the hydrophobic surface provided primarily
by Leu158 and Val170, as observed in the CATIII-
CAM structure. The side-chains of Leu158, Val160,
and Phe166 that line the very bottom of the substrate
binding pocket [Fig. 4(C)] are positioned through
interactions of the trimeric assembly and show only
minor alterations between CATI and CATIII. The
dichloroacetyl moiety of CAM closely interacts with
Phe134 (Phe135 in CATIII), likely indicating a strong
hydrophobic interaction. A major difference between
the CATI-CAM and CATIII-CAM structures is that the
residue analogous to Tyr133 of CATI is nonpolar
(Leu134) in CATIII. Tyr133 forms a strong hydrogen
bond (2.9 A˚) with the carbonyl group of CAM. Interest-
ingly, this interaction occurs in place of the interaction
of that between the hydroxyl of Tyr25 in CATIII (Phe25
in CATI) and the carbonyl group of CAM, located at an
O-O distance of 2.8 A˚ from each other.
Fusidic acid interactions in the active site
In the CATI-FA complex [Fig. 4(A)], FA occupies the
same binding site as CAM, which explains its
observed behavior as a competitive inhibitor of CAM
acetylation.13 The differences between the active site
residues of CATI (as described above) and those of
CATIII, while having little effect on CAM bind-
ing,41,44 create a unique surface suitable for binding
to FA in CATI. In particular, the placement of Ala24
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and Ala29 of CATI shapes the substrate binding cav-
ity such that the ring D and the 2-methylhex-2-ene
‘‘tail’’ of FA can be accommodated. The hydrophobic
steroid ring system of FA makes numerous hydro-
phobic contacts with active site residues, including
Thr93, Phe102, Phe134, Phe144, Ser146, Phe156,
Leu158, Val160, Phe166, and Val170 of the binding
subunit, as well as Ala24, Phe25, Val28, and Ala29
of the catalytic subunit [Fig. 4(A,C)]. The hydroxyl
moiety of ring A of FA closely aligns with the 3-
hydroxyl of CAM and forms a very strong hydrogen
bond with the Ne2 atom of His193 at a distance of
2.9 A˚ [Fig. 4(C)]. The hydroxyl group of Tyr133
points inward towards the binding pocket forming a
hydrogen bond with the hydroxyl moiety of ring C,
the atoms being separated by a distance of about 2.6
A˚ [Fig. 4(C)], similarly to the interaction between
the 3-hydroxyl and Tyr133 in the CATI-CAM struc-
ture [Fig. 3(E)]. Residues from both the binding
monomer (Phe134) and the catalytic monomer
(Ala24 and Val28) form a hydrophobic zone near the
entrance of the binding pocket in CATI that cradle
the ‘‘tail’’ section of FA and dictate its conformation
[Fig. 4(A,C)].
Valuable insight can be gained by comparing
this structure with the previously reported
Figure 4. Close-up views of interactions of FA with active-site residues of (A) CATI and (B) CATIII (quadruple mutant).
Schematic views of interactions of FA with (C) CATI and (D) CATIII (quadruple mutant). The color coding is consistent with that
of Figure 3 (FA is shown in blue). An interactive view is available in the electronic version of the article.
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structures of CATIII in complex with CAM
29 and a
quadruple mutant of CATIII in complex with FA.
43 In
the quadruple mutant of CATIII, four catalytic pocket
residues were mutated (Gln92Cys/Asn146Phe/
Tyr168Phe/Ile172Val) to mimic those of CATI. This
comparison [Fig. 4(B)] indicates a disruption of the
FA tail-interacting hydrophobic zone in the quadru-
ple mutant of CATIII, in particular due to the Ala24-
Phe and Val28Arg substitutions. The carboxylic acid
and acetoxy moieties of ring D are highly solvent
exposed when bound to both CATI and the CATIII
mutant. The acetoxy group of FA makes a hydropho-
bic contact with Phe166 in CATI (Phe168 in CATIII)
[Fig. 4(C,D)]. Despite the same general protein back-
bone scaffold of CATI and the mutant CATIII struc-
tures, there are several differences in the FA-protein
contacts for the two enzymes. Most strikingly, several
bulkier residues of CATIII: Phe24 (Ala24 in CATI),
Tyr25 (Phe25 in CATI), Arg28 (Val28 in CATI), and
Leu29 (Ala29 in CATI) prevent the FA molecule from
binding in a position similar to that in CATI. A
required shift of the FA molecule must not be accom-
modated due to structural rigidity of wild-type CATIII
resulting in the lack of binding to FA. The mutations
of the CATIII quadruple mutant apparently relax this
rigidity and surprisingly accommodate the FA mole-
cule in a very different position from that seen in the
CATI-FA structure. The hydrophobic ‘‘tail’’ of FA now
adopts a very different conformation and gets buried
in the disordered loop region (residues 138–141) of
the CATIII mutant. This disorder is very likely due to
both the Asn146Phe and the Gln92Cys substitutions
in the CATIII mutant, which cause displacement of
the His144 and Thr140 side-chains, respectively,
thereby distorting the local backbone. This displace-
ment allows the FA-tail to occupy its altered position
in the CATIII mutant.
43 Notably, Tyr25 in the CATIII
quadruple mutant structure (positionally analogous
to Phe25 of CATI) forms hydrogen bond with FA, at a
distance of 2.8 A˚ to the hydroxyl on the A-ring [Fig.
4(D)], and stabilizes the altered FA orientation.
Phe168 and Val172 residues in the CATIII quadruple
mutant make direct hydrophobic contacts with the
FA molecule, which explains the contribution of these
substitutions to the change in binding affinity to
FA.43
We observe no major differences in the backbone
conformations near the active site of CATI in the
structures of apo-CATI (PDB code: 3U9B), CATI
bound to CAM (PDB code: 3U9F), and CATI bound
to FA (PDB code: 1Q2335). This strongly suggests
that CATI has evolved to bind multiple ligands, even
as large as an FA molecule, without any major pro-
tein conformational changes in its backbone.
Discussion
Chloramphenicol acetyltransferase (CAT) is found in
many pathogenic bacteria and is often the cause of
resistance against chloramphenicol (CAM), once
a widely used antibiotic. Of many known CATs,
the type-I appears to be the most prevalent.
Recent studies have found CATI in many pathogenic
bacteria. CATI has a preference for binding to a
variety of substrates; not only does it inactivate
CAM but it also binds and sequesters other antibiot-
ics such as FA. A clear understanding of the mecha-
nism of substrate binding by CATI is important to
address the intriguing question of how CAT proteins
from different classes with similar overall structures
display different substrate selectivity profiles. In
comparison to CATIII that has been studied almost
exclusively, there are only few mechanistic studies
that have been performed on CATI.
The general fold and the trimeric organization
of CAT proteins have been observed in enzymes of
primary metabolic pathways in bacteria and eukar-
yotes, such as pyruvate dehydrogenases45,46 and
a-keto acid dehydrogenases.47,48 Therefore, CAT
appears to be a product of an ancient gene duplica-
tion event, which underwent subsequent specializa-
tion through evolution to serve a protective role
against toxic compounds such as CAM. The general
catalytic mechanism proposed for CAT proteins is
based on studies of many such proteins. The residue
primarily responsible for catalysis of CATI appears
to be His193 (His195 in CATIII).
28 This role was pro-
posed based on a previous study in which a mutant
CATIII (His195Tyr) was shown to be devoid of cata-
lytic activity.49 Another conserved residue, Ser146,
likely stabilizes the oxyanion formed upon an attack
on the AcCoA carbonyl carbon by the 3-hydroxyl of
CAM. Mutagenesis studies with CATIII confirmed
that Ser148 (Ser146 in CATI) is crucial for efficient
catalysis.42
The CATI protein structure is similar in the apo
form and in the CAM- and the FA-bound states,
indicating that no major changes in the backbone
conformations or in positions of the side-chains occur
upon ligand binding. It is quite remarkable that
such nearly rigid scaffold is evolutionarily conserved
and yet CATI can bind chemically diverse substrates.
Analysis of the aligned sequences shows that several
residues of CATI are different than corresponding
residues in CATIII. Our investigation of the CATI
structures indicates that many of these differences
are in residues lining the substrate binding pocket
(Fig. 2, blue circles). The most striking differences
are concentrated around a small patch of residues
(Ala24-Cys31, contributed by the catalytic monomer)
that enable the FA molecule to be accommodated
only in the pocket of CATI. The bulkier residues of
CATIII in this patch would push the FA towards the
opposite side of the pocket and consequently disrupt
the structure. Interestingly, the flexibility (appa-
rently resulting in the reduced rigidity and
increased disorder of the backbone) of the quadruple
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mutant of CATIII helps it accommodate the pushed
out FA in a different conformation. The ‘‘tail’’ of FA
now finds a different hydrophobic pocket to rest in
and in turn provides stability to the FA in this
altered binding pocket. The mutant CATIII shows a
200-fold higher affinity to FA than the wild-type
CATIII. However, the quadruple mutant of CATIII
binds FA with a much (4-fold) weaker affinity43 than
CATI. In addition, the Km for CAM acetylation by
the CATIII quadruple mutant was somewhat compro-
mised (with respect to either CATI or CATIII) and
the value of kcat was between those for CATIII and
CATI. With the direct structural evidence, it is now
clear how the tail of FA nests in a hydrophobic
pocket and renders CATI more energetically favor-
able to bind to FA. In CATIII, a similarly positioned
FA ‘‘tail’’ would be sterically blocked by Phe24 and
Arg28, and it is not surprising that CATIII does not
show affinity towards FA.
Our understanding of CAM’s mechanism of
action as well as the mechanisms of resistance to it
were largely based on biochemical and structural
information available on CAM binding to CATIII and
to the bacterial ribosome.4 The present structural
study augments this knowledge by filling in the gap
in our understanding of the recognition of both CAM
and FA by CATI. CAM has been largely removed
from the clinic in the Western world due to its safety
concerns, even though cases of extreme toxicity are
exceedingly rare. CAM has remained a popular drug
in underdeveloped areas due to its low cost and effec-
tiveness against a variety of pathogens. However, as
with other antibiotics, development of resistance
against CAM is a major obstacle to its power to save
lives. The detailed picture of the CATI structure is
expected to aid in design of inhibitors of CAT enzymes
that could re-sensitize CAM-resistant strains. In addi-
tion, structure-guided design of CAM analogs could
lead to new antibiotics of this class that would be less
toxic and more refractory to inactivation by CAT.
Materials and Methods
Expression and purification of CATI
CATI was expressed in BL21 (DE3)/RIL cells (Strata-
gene), which harbor a plasmid containing a constitu-
tively expressed CAM resistance gene camR
encoding untagged CATI protein. The cells were
grown in LB medium (200 rpm, 37C) containing
CAM (25 lg/mL) until the culture reached an
attenuance of 0.4 at 600 nm. The cells were har-
vested after an additional 3 h growth. Pelleted cells
(centrifugation at 5,000 g, 10 min, 4C) were resus-
pended in the lysis buffer [MES pH 6.5 (40 mM),
NaCl (200 mM), glycerol (5%), b-mercaptoethanol
(2 mM), and EDTA (0.1 mM)] and lysed by sonica-
tion. The lysate was clarified by centrifugation at
35,000  g for 45 min at 4C. We took advantage of
the thermostability of CAT proteins50 in purifying
CATI without an affinity tag. The clarified lysate
was heated (75C, 20 min) and subsequently centri-
fuged (35,000  g, 45 min, 4C) to remove unfolded
precipitated proteins. The CATI in the soluble
fraction was further purified by size-exclusion chroma-
tography on an S-200 column (GE Healthcare)
equilibrated with buffer [Tris pH 8.0 (40 mM) and
NaCl (100 mM)]. The fractions containing pure CATI,
as determined by SDS-PAGE, were concentrated to
5 mg/mL using an Amicon Ultra centrifugal filter
device (Millipore) and used for crystallization.
Crystallization of CATI alone and
in complex with CAM
Crystals of CATI alone and a complex of CATI with
CAM (CATI-CAM) were grown by vapor diffusion in
hanging drops containing 1 lL of protein and 1 lL
of the reservoir solution [HEPES (100 mM) pH 7.5
(pH of 1 M stock of HEPES acid was adjusted by
adding NaOH), PEG 4000 (20% w/v), isopropanol
(10% v/v)] or 1 lL of the reservoir solution contain-
ing CAM (1 mM), respectively. Irregularly shaped
crystals, 40–60 lm in each of the three dimensions
were formed in 7–10 days when incubated at 22C
against the respective reservoir solutions. The crys-
tals were gradually transferred into the reservoir so-
lution containing glycerol (15% v/v) and flash frozen
in liquid nitrogen.
Data collection and structure determination
X-ray diffraction data were collected at 100 K at the
25 beamline of the National Synchrotron Light
Source at the Brookhaven National Laboratory. The
data were processed with HKL2000.51 The crystals
of apo-CATI and CATI-CAM complex were in the P21
and P1 space groups, respectively. The structures of
both apo-CATI and CATI-CAM complex were deter-
mined by molecular replacement with MOLREP52 as
described in Results. The locations of the CAM mole-
cules in the active sites of CATI were clearly identi-
fied and positioned in the omit Fo-Fc density and
then refined. The structures were iteratively man-
ually built and refined using programs Coot53 and
REFMAC,54 respectively. The data collection and
refinement statistics are given in Table I. The struc-
tures of apo-CATI and CATI-CAM complex were
deposited in the Protein Data Bank with accession
codes 3U9B and 3U9F, respectively.
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